Multiple Sclerosis Injection

Under-the-skin Briumvi supported by early MS clinical trial data

Early trial data support quarterly dosing of an under-the-skin Briumvi formulation now being tested in Phase 3 for relapsing ...

STAT

FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Swiss pharma giant Roche won approval from the ...

Medical Xpress

FDA approves injectable Ocrevus Zunovo for relapsing, progressive multiple sclerosis

The U.S. Food and Drug Administration has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) as the first and only twice-a-year, 10-minute subcutaneous injection for people with relapsing ...

Healio

FDA approves first twice-a-year, subcutaneous injection for multiple sclerosis

Please provide your email address to receive an email when new articles are posted on . Genentech announced it received FDA approval for Ocrevus Zunovo to treat patients with relapsing and primary ...

TG Therapeutics Gains on Positive Data for Subcutaneous Multiple Sclerosis Drug

Shares of TG Therapeutics rose after the company reported positive data for new subcutaneous formulation of a multiple sclerosis treatment. The stock climbed 12%, to $41.21, Wednesday afternoon and is ...

Nasdaq

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

OCREVUS subcutaneous (SC) injection offers a new, 10-minute administration of OCREVUS with comparable efficacy and safety to intravenous infusion (IV) OCREVUS SC provides an additional treatment ...

Multiple Sclerosis News Today

Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive ...

The MarketWatch News Department was not involved in the creation of this content. NESS ZIONA, Israel, April 16, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Under-the-skin Briumvi supported by early MS clinical trial data

FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug

FDA approves injectable Ocrevus Zunovo for relapsing, progressive multiple sclerosis

FDA approves first twice-a-year, subcutaneous injection for multiple sclerosis

TG Therapeutics Gains on Positive Data for Subcutaneous Multiple Sclerosis Drug

Roche’s OCREVUS subcutaneous administration approved by European Commission, as first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis

CMSC 2026: Trial data show frexalimab benefits lasting 3 years

Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections

ScinoPharm Wins First FDA Approval With Glatiramer Acetate Injection For Multiple Sclerosis

Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion

Brain Injection Stopped Progression of Multiple Sclerosis in Trial of 15 People

Mapi Pharma to Present Efficacy (EDSS) Data from Glatiramer Acetate Depot Long-Acting Injection Studies in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive ...